Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (Q100500963)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

17 October 2020

title

Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

17 October 2020

1 reference

1 reference

1 reference

ORCID Public Data File 2021

author name string

RECOVERY Collaborative Group

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

17 October 2020

publication date

5 October 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

17 October 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

Estimates of the severity of coronavirus disease 2019: a model-based analysis

17 October 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Lopinavir-Ritonavir in the Treatment of COVID-19: A Dynamic Systematic Benefit-Risk Assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

A Trial of Lopinavir-Ritonavir in Covid-19. Reply

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Does lopinavir really inhibit SARS-CoV-2?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Lopinavir pharmacokinetics in COVID-19 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2820%2932013-4

7 January 2021

10.1016/S0140-6736(20)32013-4

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:33031764%20AND%20SRC:MED&resulttype=core&format=json

17 October 2020

1 reference